The report was based on survey responses from more than 300 U.S. pharmacies.
The average cost of Lispro for uninsured patients was $97.51 — nearly four times higher than the $25 price cap set by Eli Lilly. In addition, 42 percent of the surveyed pharmacies did not have the lower-priced generic in stock.
Eli Lilly, Sanofi and Novo Nordisk — the nation’s three largest insulin manufacturers — all announced insulin price cuts in March. While most of these price drops take effect in late 2023 and 2024, Eli Lilly rolled out a cap for Lispro this May.
Editor’s note: Becker’s has reached out to Eli Lilly for comment and will update the article as more information becomes available.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
